Screener
Madrigal Pharmaceuticals, Inc. MDGL Long-Term Debt
Long-Term Debt at other companies
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtNoncurrent.
The source filing: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 9:06 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050845
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Operating lease liabilities | 1,034 | 1,018 |
| Total current liabilities | 374,204 | 310,288 |
| Long term liabilities: | ||
| Loan payable, net of discount | 340,794 | 339,881 |
| Operating lease liabilities, net of current portion | 5,923 | 6,731 |
| Total long term liabilities | 346,717 | 346,612 |
| Total liabilities | 720,921 | 656,900 |
| Stockholders’ equity: |
Item 1. Financial Statements (Unaudited):
FAQ
- What is Madrigal Pharmaceuticals, Inc.'s long-term debt?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported long-term debt of $340.79M in Q2 2026.
- How has Madrigal Pharmaceuticals, Inc.'s long-term debt changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s long-term debt increased by 187.9% year-over-year, from $118.38M to $340.79M.
- What does long-term debt mean?
- Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.
Ask your AI about Madrigal Pharmaceuticals, Inc.'s long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude